GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » EBITDA per Share

MedTech Acquisition (MedTech Acquisition) EBITDA per Share : $0.00 (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition EBITDA per Share?

MedTech Acquisition's EBITDA per Share for the three months ended in Jun. 2023 was $0.00. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for MedTech Acquisition's EBITDA per Share or its related term are showing as below:

MTACU's 3-Year EBITDA Growth Rate is not ranked *
in the Diversified Financial Services industry.
Industry Median: 16.5
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

MedTech Acquisition's EBITDA for the three months ended in Jun. 2023 was $-1.43 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


MedTech Acquisition EBITDA per Share Historical Data

The historical data trend for MedTech Acquisition's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition EBITDA per Share Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
EBITDA per Share
- - -

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MedTech Acquisition EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MedTech Acquisition's EBITDA per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA per Share(A: Dec. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-2.746/0
=N/A

MedTech Acquisition's EBITDA per Share for the quarter that ended in Jun. 2023 is calculated as

EBITDA per Share(Q: Jun. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-1.43/0
=N/A

EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedTech Acquisition  (NAS:MTACU) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


MedTech Acquisition EBITDA per Share Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MedTech Acquisition (MedTech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
48 Maple Avenue, Greenwich, CT, USA, 06830
Website
MedTech Acquisition Corp is a blank check company.
Executives
Magnetar Financial Llc 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc 10 percent owner 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman 10 percent owner C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell director 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin director, 10 percent owner, officer: Chief Financial Officer
Karim Karti director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey director, 10 percent owner, officer: Chief Executive Officer 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss officer: Chief Admin Officer and Sec. 585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022

MedTech Acquisition (MedTech Acquisition) Headlines